Enabling Genomics in Practice.

We partner with clinicians and medical
facilities to advance clinical genomics and
modernize patient care. 

In 2003, Washington University in St. Louis mapped the first human genome, triggering the start of our journey. Since then, we have been working with clinicians and medical facilities as their partners in precision medicine.

2003

2003

Human Genome Complete

Washington University in St. Louis plays a crucial role in the mapping of the first human genome.

Washington University in St. Louis seal

2011

2011

Washington University creates a CAP/CLIA lab for NGS testing. The Genetics and Molecular Pathology departments collaborate to develop Clinical Genomics Workspace (CGW), a groundbreaking software platform for clinical genomics.

FP_Pierian WF icons_desktop 1

2012/2013

2012/2013

More than 50 laboratories visit Washington University to learn how to operationalize clinical NGS testing.

st-louis-arch

2014

2014

Washinton University performs a technology transfer, Pierian is officially established, and our first office is opened in St. Louis, Missouri, USA.

St Louis

2015

2015

We secure Series A funding after two releases of CGW that offer multi-tenant and exome sequencing support.

partner

2016

2016

We open a second office in Pune, India, to support software development and large-scale biocuration efforts.

india copy

2017

2017

We reach 40+ customers supported by 70+ medical, scientific, and technical experts.

NovaSeq machine

2018

2018

An agreement is finalized with Illumina, our first assay partner, and we prepare for a collaboration launch to deliver optimized interpretation and reporting solutions for Illumina pan-cancer profiling assays.

world icon

2019

2019

We close $27 million Series B funding to support growth in global markets.

2020

2020

We exceed 100 customers due to rapid expansion into Europe, the Middle East, and the Asia Pacific regions.

Icon of a group of people

2021

2021

We secure $47.5 million in additional funding to drive expansion across new assays, new customer segments, and new geographies.